Apr 7, 2026 08:00AM
Mar 26, 2026 08:02AM
Mar 26, 2026 08:00AM
Mar 16, 2026 08:02AM
Mar 16, 2026 08:00AM
Nov 19, 2025 08:01AM
Nov 19, 2025 08:00AM Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital
Jul 28, 2025 08:00AM
Jul 23, 2025 08:00AM
Jun 16, 2025 08:00AM
May 29, 2025 08:04AM
May 29, 2025 08:00AM
May 19, 2025 08:03AM
May 19, 2025 08:00AM Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
May 13, 2025 08:00AM
May 8, 2025 08:01AM
May 8, 2025 08:00AM
May 7, 2025 08:00AM
Mar 25, 2025 08:00AM
Mar 18, 2025 08:00AM
Mar 11, 2025 08:00AM Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital
Mar 4, 2025 08:11AM
Mar 4, 2025 08:10AM
Feb 25, 2025 08:00AM
Feb 19, 2025 08:04AM
Feb 19, 2025 08:00AM
Jan 15, 2025 08:00AM
Dec 18, 2024 08:00AM Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo
Dec 12, 2024 08:00AM
Nov 19, 2024 08:02AM
Nov 19, 2024 08:00AM
Oct 16, 2024 08:06AM
Oct 16, 2024 08:00AM
Oct 15, 2024 08:04AM
Oct 15, 2024 08:00AM Alzamend Neuro Regains Compliance with Nasdaq Listing Standards
Oct 10, 2024 08:00AM
Aug 26, 2024 08:04AM
Aug 26, 2024 08:00AM
Aug 19, 2024 08:06AM
Aug 19, 2024 08:00AM
Aug 12, 2024 08:03AM
Aug 12, 2024 08:00AM Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Dis
Aug 6, 2024 08:00AM
Aug 5, 2024 09:10AM
Aug 5, 2024 09:09AM
Jul 31, 2024 08:00AM
Jul 31, 2024 08:00AM
Jul 12, 2024 08:00AM
Jul 12, 2024 08:00AM Alzamend Neuro Announces Reverse Stock Split
May 22, 2024 08:04AM

1,197,524 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All